
AbbVie's Investigational Compound Receives Orphan Drug Designation by Both the FDA and EMA
ABT-414 is being developed to treat glioblastoma multiforme.
AbbVie (NYSE:ABBV) today
"The orphan drug designation is an important regulatory advancement as we further our development in recurrent glioblastoma multiforme, a disease that is uniformly fatal with limited treatment options," said Gary Gordon, M.D., vice president, oncology clinical development, AbbVie. "We are pleased to continue developing ABT-414 in Phase II trials in patients with glioblastoma multiforme based on the results of our Phase I program."
Results from the Phase I clinical program evaluating ABT-414 in patients with recurrent or unresectable glioblastoma multiforme were presented at the 50(th) American Society of Clinical Oncology (ASCO) meeting in Chicago earlier this year.
Source: The Wall Street Journal
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.